论文部分内容阅读
目的探讨参附注射液治疗急性心肌梗死患者的临床疗效。方法以2014年1月-2015年1月济源市人民医院接收的急性心肌梗死患者98例为观察对象,随机分为观察组和对照组各49例,对照组采用常规治疗,观察组在常规治疗的基础上加用参附注射液,治疗2周后,比较两组临床总有效率,超氧化物岐化酶(SOD)、C反应蛋白(CRP)、N末端脑钠肽前体(NT-proBNP)水平以及心功能心输出量(CO)、左室射血分数(LVEF)。结果经过治疗观察组临床总有效率高于对照组,观察组SOD水平高于对照组,CRP、NT-proBNP水平低于对照组,CO以及LVEF高于对照组,比较差异具有统计学意义(P<0.05)。结论在急性心肌梗死患者的治疗中,通过参附注射液的加用,改善了患者的心功能,增强患者清除氧自由基能力,保护患者的心肌健康。
Objective To investigate the clinical efficacy of Shenfu injection in the treatment of patients with acute myocardial infarction. Methods From January 2014 to January 2015, 98 patients with acute myocardial infarction received by Jiyuan People’s Hospital were randomly divided into observation group (49 cases) and control group (49 cases). The control group received routine treatment and the control group received conventional therapy After 2 weeks of treatment, the total clinical effective rate, superoxide dismutase (SOD), C-reactive protein (CRP) and N-terminal pro brain natriuretic peptide (NT- proBNP) and cardiac output (CO), left ventricular ejection fraction (LVEF). Results The total clinical effective rate in the treatment group was higher than that in the control group. The SOD level in the observation group was higher than that in the control group. The levels of CRP and NT-proBNP in the observation group were lower than those in the control group. The CO and LVEF were higher in the observation group than in the control group <0.05). Conclusions In the treatment of patients with acute myocardial infarction, Shenfu injection can improve the cardiac function, enhance the ability of patients to scavenge oxygen free radicals and protect the myocardial health of patients.